Myeloid Therapeutics to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
CAMBRIDGE, Mass., April 15, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, today announced its participation at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, taking place virtually April 29-30.
Daniel Getts, Ph.D., Chief Executive Officer of Myeloid, will participate in a fireside chat on Monday, April 29, 2024, at 11:30 am ET. Company management will also participate in one-on-one meetings with investors during the event.
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA.
On May 14, 2024, MHR Fund Management LLC ("Fund Management") filed an amended early warning report in accordance with Section 5.2(2)(b) of National Instrument 62-104 ? Take-Over Bids and Issuer Bids (the "Early Warning Report") for Lions Gate...
The global flow cytometry market size is estimated to grow by USD 6038.44 million from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of about 13.12% during the forecast period....
TerraPay, a prominent global money movement company, has partnered with Al Ansari Exchange, the largest remittance and foreign exchange company in the UAE and a subsidiary of Al Ansari Financial Services PJSC [DFM: ALANSARI]. TerraPay's global...
On or around February 6, 2024, Hypertension-Nephrology Associates, P.C. ("the Practice") became aware it was the target of an extortion attack when an extortion note was found on its computer system. Upon discovery of the extortion note, the Practice...
KRAFTON Inc. (CEO CH Kim, KRX: 259960) announced its 1Q24 preliminary earnings on May 8.
KRAFTON recorded its 1Q24 sales of 665.9B South Korean Won, Operating Profit (OP) of 310.5B KRW, and Net Profit (NP) of 348.6B KRW following the Korean...
